Cerus lifts full-year outlook as Q2 revenue climbs 10% and losses narrow
CERS has more than doubled off its 52-week low of $1.15.
Summary
Cerus posted Q2 2026 product revenue of $57.4M (+10% YoY), raised full-year product revenue guidance to $229M–$231M, and narrowed its net loss to $2.9M. Gross margins slipped to 51% on tariffs and FX. Cash and investments stood at $56.9M. The CFO and CLO adopted 10b5-1 trading plans in May.
Key Events · Earnings and Guidance · CERS
-
Q2 Revenue +10%, Guidance Raised
Product revenue reached $57.4M, up 10% YoY, driven by platelet kit and IFC sales. Full-year product revenue guidance raised to $229M–$231M.
-
Net Loss Narrows Sharply
Net loss attributable to Cerus was $2.9M ($0.01/share) vs. $5.7M ($0.03/share) in Q2 2025, helped by lower R&D spend and operating leverage.
-
Gross Margin Pressure from Tariffs
Gross margin on product revenue fell to 51% from 55% a year ago, primarily due to tariffs and unfavorable foreign exchange rates.
-
Debt Refinancing Completed
On June 5, 2026, Cerus refinanced its term loan, reducing the balance to $35M (from $65M) and expanding its revolving credit facility to $30M. Total debt at quarter-end was $64.9M.
Analysis · CERS · Industrial Applications And Services
A solid quarter for Cerus saw product revenue advance 10% to $57.4 million, prompting management to raise the full-year product revenue target to $229–$231 million. The net loss contracted meaningfully to $2.9 million from $5.7 million a year ago, and operating cash burn improved. Offsetting those gains, gross margins compressed to 51% from 55% under the weight of tariffs and foreign exchange headwinds. The company closed the quarter with $56.9 million in cash and investments and recently refinanced its debt, trimming the term loan to $35 million while expanding the revolver to $30 million. The filing also revealed that the CFO and CLO adopted 10b5-1 trading plans in May, and no shares were sold under the ATM program during the quarter. While the raised guidance and shrinking losses are encouraging, margin pressure and the overhang from the ATM and insider selling plans temper the outlook.
At the time of this filing, CERS was trading at $2.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $579.1M. The 52-week trading range was $1.15 to $3.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.